Financial PerformanceFinancial update for 4Q showed a loss per share of $0.64, below estimates, with R&D and G&A expenses rising significantly YoY.
Market Adoption ConcernsConcerns exist about the safety risk of bato compared to competitors, which could limit its adoption in the market.
Stock PerformanceShares are down -44% YTD as investors continue to await meaningful catalysts from IMVT-1402.